John Molina, MD, MEd

The panel discusses the efficacy of belantamab mafoditin and where the treatment fits in the multiple myeloma treatment landscape.

Craig Cole, MD, reviews data from DREAMM-3 on the efficacy and safety of single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma.

Experts on multiple myeloma discuss the clinical applications of ixazomib-lenalidomide-dexamethasone combination therapy.

John C. Molina, MD, EdM, reviews data from the 3-year update from the OPTIC study, and other experts offer their impressions.

Experts in the field of chronic myeloid leukemia discuss the role of asciminib in the overall treatment landscape.

Faiz Answer, MD, FACP, reviews data from the REMIX study on the real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma.

Experts in the field of multiple myeloma discuss data from a retrospective study on patients with multiple myeloma.

Charles A. Schiffer, MD, reviews clinical trial data for asciminib in chronic myeloid leukemia and highlights financial toxicity concerns.

The expert panel discusses the potential role of olverembatinib in the chronic myeloid leukemia treatment landscape.

Jeffrey A. Zonder, MD, reviews data on patient outcomes following biochemical or clinical progression in multiple myeloma.

The expert panel discusses the efficacy and durability of response of ciltacabtagene autoleucel in patients with multiple myeloma.

Moaath Mustafa Ali, MD, MPH, reviews data on olverembatinib in patients with heavily pretreated/refractory chronic myeloid leukemia.

Expert perspectives on treatment considerations for ponatinib in patients with chronic myeloid leukemia.

Jack Khouri, MD, discusses phase 3 results from the CARTITUDE-4 study investigating ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma.

Following a review of data from the ALLIANCE A061202 study, experts on multiple myeloma discuss treatment considerations for patients being treated with ixazomib, pomalidomide, and dexamethasone.

Jay Yang, MD, reviews data from the OPTIC trial, a ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia.

A panel of experts on chronic myeloid leukemia from Karmanos Cancer Institute and Cleveland Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent data in the disease space.

Andrew Kin, MD, reviews data on the addition of ixazomib to pomalidomide and dexamethasone in patients with multiple myeloma who progressed on lenalidomide in the first line.

A panel of experts on multiple myeloma from Karmanos Cancer Institute and Cleveland Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent data in multiple myeloma.